I sent another query regarding some of the questions I had and about LC abstaining from the vote, raising capital when LC said they wouldn’t be, the reduction of the companies’ platforms from 5 to 3, plus the delay of trial data. They took the time and provided a response.
You are referencing this statement inthe Notice of Meeting.
“The Directors (with Ms Leslie Chong abstaining) unanimously recommend that you votein favour of this resolution.”
There is a difference between the directors' recommendation (based upon variousgovernance principles and as reflected in the Notice of Meeting prepared inconjunction with our advisors) and the ability of directors to vote theirshares. IMU can confirm that the CEO was eligible to and did vote on theresolutions (having no material personal interest or related party interests).The resolutions were passed on a poll with 98.58% and 98.57% voting FOR theresolutions respectively.
“We don’t spend time telling the marketour strategy re capital. Historically over the last 4-5 years we have alwaysbeen well supported when we need money. The board watches the cash positioncarefully and we will make an announcement when we have made a decision.
The board monitors the market & cash position carefully, they are in touch with bankers and investors and at theappropriate time, we'll let the market know as to our efforts or outcomes to raise money”
The B-cell platform has not been dropped.
HER-Vaxx studies have completed, andstudies have been closed.
The data continues to be published andpresented. As advised to the market several times, we continue to pursueout-licensing opportunities for the technology
PD1-Vaxx is in a Phase 1 trial, known asNeo-POLEM is an Investigator Sponsored Trial (IST) and will recruit patients insites in Australia and the UK. The trial is expected to recruit approximately44 patients with colorectal cancer. Treatment with PD1-Vaxx will beadministered before surgery (neoadjuvant). This study is expected tostart in the first half of 2025. As previously stated, the B-cellimmunotherapies have been deprioritized to focus on the azer-cel program andthe Oncolytic Virus platform. Management continues to pursue out-licensingopportunities for its B-cell immunotherapies
Imugene is committed to trial integrity and clinicaldevelopment of our prioritized programs. Any delays or revising timelines is toensure long-term benefit to the patients and the company. For example,the addition of interleukin 2 (IL-2) to azer-cel increased the T-cells in ourpatients which appears to increase clinical response and durability (how longthe patients maintain their efficacy or response) which has produced promisinginitial data. The trial requires further patients to be enrolled in thiscombination with low dose IL-2 to achieve a statistical number for a regulatorypackage. The MAST study, the trial requires further interrogationof the highest dose possible to achieve the optimal biological dose(recommended phase 2 dose) and since we have seen no safety issues, we continueto dose escalate to find the protocol endpoint which is to achieve optimalbiological dose/recommended phase 2 dose (OBD/RP2D) in order to proceed. You can only establish an OBD or RP2D once, in order to change a RP2D ,the company has to conduct additional phase 1 trial.
(20min delay)